Short, sourced explanations of the terms, rules, and measures behind breast imaging operations. Each one covers what it is, how it works, and why it matters.
One published benchmark comes from the CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which uses a program benchmark of 60 days or less from an abnormal screening result to diagnosis. In a study of that program's data, the authors report a median diagnostic interval of 25 days for 1996 to 2000 and 23 days for 2001 to 2005.
How it works
The study analyzed program data for 382,416 women with an abnormal mammogram or clinical breast examination, 23,701 of whom were diagnosed with breast cancer. The authors report that the share of women diagnosed within the 60 day benchmark improved the most, from 77 percent to 82 percent, among women with a normal mammogram and an abnormal clinical breast examination. These figures describe one national screening program. The MQSA audit rule requires follow-up of positive mammograms but states no time limit for reaching a diagnosis, so the 60 days is a program benchmark and not a federal requirement for a facility.
Why it matters
A facility can use a published benchmark to judge its own turnaround, as long as it says which program the figure comes from.
What it means to the patient or the client
For the client: if you track the time from an abnormal screen to a diagnosis, compare your median and the share within 60 days with this program's figures, and name the source when you report it.
Sources
Richardson LC, Royalty J, Howe W, Helsel W, Kammerer W, Benard VB. Timeliness of breast cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program, 1996-2005. Am J Public Health. 2010;100(9):1769-1776. doi:10.2105/AJPH.2009.160184. PubMed PMID 20019308. Accessed October 7, 2026. https://pubmed.ncbi.nlm.nih.gov/20019308/ View source (accessed October 7, 2026)
In a study of the CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP), the authors report a median treatment initiation interval, the time from diagnosis to the start of treatment, of 12 days in 1996 to 2000 and 14 days in 2001 to 2005, against a program benchmark of 60 days or less.
How it works
The authors also report that the median total interval from screening to treatment was 43 days in the first period and 40 days in the second, and they examined the share of women starting treatment within 120 days of screening. They conclude that women screened by the program received diagnostic follow-up and started treatment within the program's preestablished guidelines. The data come from women who had an abnormal mammogram or clinical breast examination in that program, so they are a reference point, not a standard that applies to every practice.
Why it matters
Treatment timing is a reasonable measure of the whole pathway, but it only helps a practice if the practice can see the dates.
What it means to the patient or the client
For the client: an imaging center usually controls the screening to diagnosis steps and sees the treatment date only if it receives that information back, so decide which of these intervals your tracking can capture before you adopt a target.
Sources
Richardson LC, Royalty J, Howe W, Helsel W, Kammerer W, Benard VB. Timeliness of breast cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program, 1996-2005. Am J Public Health. 2010;100(9):1769-1776. doi:10.2105/AJPH.2009.160184. PubMed PMID 20019308. Accessed October 7, 2026. https://pubmed.ncbi.nlm.nih.gov/20019308/ View source (accessed October 7, 2026)
The American Cancer Society says the diagnosis is made from a rapid onset of breast redness and swelling covering at least a third of the breast, together with invasive cancer found on biopsy.
How it works
Its page lists the signs: swelling of the breast skin, redness over at least a third of the breast, pitting or thickening of the skin that can look like an orange peel, tenderness, warmth, or heaviness, and swollen lymph nodes under the arm or near the collarbone. Imaging may include a mammogram, a breast ultrasound, and a breast MRI, and a photograph of the breast is often taken to record the redness and swelling before treatment. A punch biopsy of the abnormal breast skin is typically done to confirm the diagnosis. The page notes that the symptoms can look like an infection, that a doctor may first treat with antibiotics, and that patients should tell their doctor if symptoms last about a week without improving. It does not give a required time from imaging to biopsy.
Why it matters
Inflammatory breast cancer can be mistaken for infection, so an unresolved red, swollen breast needs a follow-up plan.
What it means to the patient or the client
For the client: if you build an urgent pathway, set your own timing targets with your radiologists and document them, because the ACS page gives no mandated times. Make sure a patient with these symptoms who is told to return after antibiotics has a tracked follow-up date.
Sources
American Cancer Society. Inflammatory breast cancer. Last revised June 24, 2026. Accessed October 7, 2026. https://www.cancer.org/cancer/types/breast-cancer/types-of-breast-cancer/inflammatory-breast-cancer.html View source (accessed October 7, 2026)
The American Cancer Society lists criteria for people already diagnosed with breast cancer, and a second group of people without a current diagnosis, for whom genetic counseling and testing is more likely to help.
How it works
For people already diagnosed, the listed criteria are diagnosis at a younger age, especially before 50, triple negative breast cancer, a second breast cancer that is not a recurrence, multiple breast cancers at the same time, Ashkenazi Jewish descent, a family history of breast cancer (especially at a younger age or in men), a family history of ovarian, pancreatic, or prostate cancer, a gene change found on tumor testing, and lobular breast cancer with a personal or close family history of diffuse gastric cancer. For people without a diagnosis, the page names those with a known family BRCA mutation or similar variant, women with ovarian or pancreatic cancer, men with breast, pancreatic, or advanced prostate cancer, and those with multiple affected relatives or early onset cancers in the family. A genetic counselor reviews family history and explains what testing would mean. The page, last revised March 30, 2026, says it is more helpful for people meeting these criteria, not that everyone needs it.
Why it matters
These criteria help a facility decide when a patient's history is worth a conversation about referral.
What it means to the patient or the client
For patients: if your family history matches any of these, ask your healthcare provider about genetic counseling. For the client: if your intake form collects family history, use these criteria to flag patients for the provider to review. The provider decides on referral, not the facility.
Sources
American Cancer Society. Genetic counseling and testing for breast cancer risk. Last revised March 30, 2026. Accessed October 7, 2026. https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/genetic-testing.html View source (accessed October 7, 2026)
NAPBC Standard 5.2 (2024) covers patients with a clinical finding or an abnormal mammogram. It requires a protocol with risk evaluation during the diagnostic process, access to biopsy services, and performance of a recommended biopsy or notification of the patient about the recommendation.
How it works
The program must also have a process for radiology and pathology to review concordance between imaging and biopsy results, with the decision and a recommended action documented in the medical record, and a process for following up on any recommended action. Each accreditation cycle the breast leadership committee must review barriers to efficient diagnosis, such as turnaround time for core biopsy results, the handling of discordant biopsies, and the processes for patient follow-up, biopsy recommendations, and biopsy results, and it must address any barriers found and record that in its minutes. MQSA requires follow-up of positive mammograms and pathology correlation for the audit, but it does not set these program level reviews.
Why it matters
NAPBC adds a documented follow-up and concordance process on top of the MQSA minimum.
What it means to the patient or the client
For the client: if you are preparing for NAPBC, make sure your tracking can show recommended biopsies performed or communicated, concordance decisions with their actions, and the turnaround times the committee reviews.
Sources
American College of Surgeons. Optimal Resources for Breast Care: 2024 Standards (National Accreditation Program for Breast Centers). Accessed October 7, 2026. https://accreditation.facs.org/accreditationdocuments/NAPBC/Standards/Optimal_Resources_for_Breast_Care_2024.pdf View source (accessed October 7, 2026)
MammoNavigate is the Mammologix service pillar that makes next steps easier to see. It helps spot follow-up recommendations sooner, track what is pending, and keep follow-up moving [1].
How it works
Mammologix structures worklists around how a facility's team manages patient movement, and organizes views by recommendation path so staff can follow the right workflow. It accommodates client-specific preferences and real-world operational branching instead of rigid templates. Touchpoints include overdue follow-up, lost to follow-up, referral, scheduling, triage, same day biopsy, and additional imaging [1].
Why it matters
Staff can pinpoint what is still pending, what has been done, and what needs action. That makes continuity of care easier to maintain and patient slippage easier to spot.
What it means to the patient or the client
The practice gets navigation tools shaped to its own workflow, including unusual requirements.
Sources
Mammologix. Visible workflows. Verified follow-up. Audit-ready output. Mammologix.com. Accessed October 7, 2026. https://mammologix.com/results View source (accessed October 7, 2026)
21 CFR 900.12(c)(2) has two rules for patients who do not name a healthcare provider to receive the mammography report.
How it works
The patient receives the full mammography report, as well as the written lay summary of the results, within 30 days. If the assessment is Suspicious or Highly Suggestive of Malignancy, the report goes to the patient within 7 calendar days of the final interpretation of the mammograms. Each facility that accepts patients without a healthcare provider must also maintain a system for referring them to a healthcare provider when clinically indicated, which must include cases where the assessment is Probably Benign, Suspicious, or Highly Suggestive of Malignancy.
Why it matters
For these patients the facility is the only recipient of the result, so the report timing and the referral system are the safety net.
What it means to the patient or the client
For patients: if you have no healthcare provider, the facility must still send you your results and help connect you with a provider when your result calls for it. For the client: document your referral process and test it for the three assessment categories.
Sources
21 CFR §900.12. Quality standards. eCFR. Accessed October 7, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-I/part-900/subpart-B/section-900.12 View source (accessed October 7, 2026)
